-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Jazz Pharmaceuticals, Raises Price Target to $281

Benzinga·08/26/2026 14:22:51
Listen to the news
Truist Securities analyst Gregory Renza maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and raises the price target from $264 to $281.